CSL-Ltd-CSLAX-Deep-dive-into-Pipeline-A12-to-Target-Price.pdf
This is a recently released Goldman Sachs report detailing the current R&D landscape for CSL. It provides the rational behind their $312 target price. Of course, with all broker reports you have to take them with a grain of salt. However, they explore each of the 15 projects in/near active development, assessing the data and the likely regulatory pathway and financial impact. Awesome read for anyone wanted a breakdown of the underlying molecules, the target markets and the overall opportunities. I feel sorry for the intern Riashad Monjur, who gets a brief shoutout for probably writing the whole thing. As usual DYOR.
Goldman Sachs R&D Report
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$277.01 |
Change
-7.040(2.48%) |
Mkt cap ! $134.1B | |||
| Open | High | Low | Value | Volume |
| $280.67 | $281.07 | $275.01 | $254.8M | 915.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1140 | $277.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $277.08 | 312 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CSL (ASX) Chart |